NAD+ regulatory status
Current status of NAD+ in the United States: Under FDA review. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of NAD+?
Regulatory: Under FDA reviewWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- NAD+ (nicotinamide adenine dinucleotide) is not an FDA approved drug. It was nominated for the FDA 503A bulks list and appears on the nominated substances lists pending FDA evaluation; no final rule placing it on or excluding it from the bulks list had been published as of the last verification date, so compounded NAD+ injections and infusions are dispensed under FDA's interim enforcement policy where state boards permit. Oral NR and NMN are sold as dietary supplements, and FDA has questioned whether NMN qualifies as a dietary ingredient because of prior drug investigation.
- WADA
- Not WADA prohibited
- Access path
- Over the counter dietary supplement precursors (nicotinamide riboside, nicotinamide mononucleotide), no prescription needed.
- Prescription from a licensed provider filled by a 503A compounding pharmacy for injectable NAD+, where the state board permits it.
- Clinic or telehealth programs offering NAD+ infusions or injections.
Full NAD+ page: evidence, dosing in the literature, and sources
How has the status of NAD+ changed over time?
No dated regulatory event has been recorded for NAD+. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for NAD+ and the source of each dated event.